Interestingly, some retrospective studies showed that CD19 loss during treatment may be a less frequent resistance mechanism in DLBCL compared to B-cell acute lymphoblastic leukemia with only 6% of relapse samples showing a loss of CD19 [10]. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.